Sab bio announces third quarter 2024 financial results and provides company update

Company announced completed phase 1 enrollment for sab-142 with no observation of serum sickness. the company remains on track for a topline phase 1 data readout by the end of the year.

SABS Ratings Summary

SABS Quant Ranking